RECORD // Company

Summit Therapeutics Inc.

Formerly: Summit Therapeutics plc; Summit Corp plc

Built 2026-11-21T11:32:08Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Matched by name only, not merged (25)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • SUMMIT, THE · Cms inspections · 'Summit' is an ordinary word shared by many unrelated entities Possible match based on name, not a shared identifier. Compare the records. Compare
  • THE SUMMIT · Cms inspections · 'Summit' is an ordinary word shared by many unrelated entities Possible match based on name, not a shared identifier. Compare the records. Compare
  • Summit LLC · Corp enforcement · 'Summit' is an ordinary word shared by many unrelated entities Possible match based on name, not a shared identifier. Compare the records. Compare
  • Summit Therapeutics Inc. · Ct business · same registered legal name as 'Summit Therapeutics Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • Summit Therapeutics · Ctgov · name equals 'Summit Therapeutics' but other unrelated entities share it Possible match based on name, not a shared identifier. Compare the records. Compare
  • The Summit · East food · 'Summit' is an ordinary word shared by many unrelated entities Possible match based on name, not a shared identifier. Compare the records. Compare
  • Summit · East licences · 'Summit' is an ordinary word shared by many unrelated entities Possible match based on name, not a shared identifier. Compare the records. Compare
  • Summit Therapeutics, Inc. · East licences · same registered legal name as 'Summit Therapeutics Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • Summit LLC · East spend · 'Summit' is an ordinary word shared by many unrelated entities Possible match based on name, not a shared identifier. Compare the records. Compare
  • SUMMIT · Epa echo · 'Summit' is an ordinary word shared by many unrelated entities Possible match based on name, not a shared identifier. Compare the records. Compare
  • SUMMIT (COLLECTION AND RECYCLING CENTER) · Epa echo · 'Summit' is an ordinary word shared by many unrelated entities Possible match based on name, not a shared identifier. Compare the records. Compare
  • Summit, CO (County law enforcement agency) · Fbi crime · 'Summit' is an ordinary word shared by many unrelated entities Possible match based on name, not a shared identifier. Compare the records. Compare
  • THE SUMMIT · Local3 · 'Summit' is an ordinary word shared by many unrelated entities Possible match based on name, not a shared identifier. Compare the records. Compare
  • Summit · Local5 · 'Summit' is an ordinary word shared by many unrelated entities Possible match based on name, not a shared identifier. Compare the records. Compare
  • Summit, The · Local5 · 'Summit' is an ordinary word shared by many unrelated entities Possible match based on name, not a shared identifier. Compare the records. Compare
  • THE SUMMIT · Local5 · 'Summit' is an ordinary word shared by many unrelated entities Possible match based on name, not a shared identifier. Compare the records. Compare
  • Summit · Msha mines · 'Summit' is an ordinary word shared by many unrelated entities Possible match based on name, not a shared identifier. Compare the records. Compare
  • Summit · Msha mines · 'Summit' is an ordinary word shared by many unrelated entities Possible match based on name, not a shared identifier. Compare the records. Compare
  • Summit Inc · Msha mines · 'Summit' is an ordinary word shared by many unrelated entities Possible match based on name, not a shared identifier. Compare the records. Compare
  • Summit Inc · Msha mines · 'Summit' is an ordinary word shared by many unrelated entities Possible match based on name, not a shared identifier. Compare the records. Compare
  • SUMMIT LLC · Mw hearings · 'Summit' is an ordinary word shared by many unrelated entities Possible match based on name, not a shared identifier. Compare the records. Compare
  • SUMMIT · Ncua · 'Summit' is an ordinary word shared by many unrelated entities Possible match based on name, not a shared identifier. Compare the records. Compare
  • SUMMIT · Ncua · 'Summit' is an ordinary word shared by many unrelated entities Possible match based on name, not a shared identifier. Compare the records. Compare
  • SUMMIT · Ncua · 'Summit' is an ordinary word shared by many unrelated entities Possible match based on name, not a shared identifier. Compare the records. Compare
  • THE SUMMIT · Ncua · 'Summit' is an ordinary word shared by many unrelated entities Possible match based on name, not a shared identifier. Compare the records. Compare

2 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-04 · accession 0001599298-26-000090

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$-208,385,0003 months ended 2026-09-3010-Q2026-11-040001599298-26-0000902026-11-21 11:32 UTCReport an error
Cash and cash equivalents$150,811,000at 2026-09-3010-Q2026-11-040001599298-26-0000902026-11-21 11:32 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Revenue, Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001599298
Ticker
SMMT
EIN
371979717
CUSIP
86627T108
Record ID
sx:sec:0001599298

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

42 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-20SEC EDGAR company profile2026-11-21 11:32 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-20SEC EDGAR company profile2026-11-21 11:32 UTCReport an error
Fiscal year end (MMDD)12312026-11-20SEC EDGAR company profile2026-11-21 11:32 UTCReport an error
Business address601 BRICKELL KEY DRIVE, SUITE 1000, MIAMI, FL, 331312026-11-20SEC EDGAR company profile2026-11-21 11:32 UTCReport an error
ExchangesNasdaq2026-11-20SEC EDGAR company profile2026-11-21 11:32 UTCReport an error
Revenue (fiscal year ended 2024-12-31)$02024-12-3110-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax2026-11-21 11:32 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-1,079,586,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-21 11:32 UTCReport an error
Total assets (at 2025-12-31)$751,182,0002025-12-3110-K, XBRL Assets2026-11-21 11:32 UTCReport an error
Stockholders' equity (at 2025-12-31)$658,860,0002025-12-3110-K, XBRL StockholdersEquity2026-11-21 11:32 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$225,266,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-21 11:32 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-322,930,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-21 11:32 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$657,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-21 11:32 UTCReport an error
Operating lease liabilities (at 2025-12-31)$20,890,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-21 11:32 UTCReport an error
Form D total offering amount (D filed 2024-09-26)$234,999,8892024-09-26D2026-11-21 11:32 UTCReport an error
Form D total amount sold (D filed 2024-09-26)$234,999,8892024-09-26D2026-11-21 11:32 UTCReport an error
Form D industry groupBiotechnology2024-09-26D2026-11-21 11:32 UTCReport an error
Form D revenue rangeDecline to Disclose2024-09-26D2026-11-21 11:32 UTCReport an error
Form D date of first sale2024-09-112024-09-26D2026-11-21 11:32 UTCReport an error
8-K Item 8.01 (filed 2026-11-18)Other Events. On November 18, 2026, Summit Therapeutics Inc. issued a press release announcing the planned initiation of the global Phase III HARMONi-10 trial (“HARMONi-10”). HARMONi-10 will evaluate ivonescimab compared with durvalumab as consolidation therapy in patients with locally advanced, unresectable Stage III non-small cell lung cancer who have not experienced disease progression following platinum-based concurrent chemoradiation therapy. Global clinical trial site activations for HARMONi-10 are expected to begin in the fourth quarter of 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.2026-11-18SEC EDGAR 8-K 0001599298-26-000094 (text as filed, excerpt)2026-11-21 11:32 UTCReport an error
8-K Item 8.01 (filed 2026-11-16)Other Events. On November 15, 2026, Summit Therapeutics Inc. issued a press release announcing that the U.S. Food and Drug Administration (the “FDA”) has issued a Complete Response Letter (“CRL”) regarding the Biologics License Application (“BLA”) for ivonescimab in combination with platinum-containing chemotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer, who have received prior epidermal growth factor receptor tyrosine kinase inhibitor therapy. The CRL indicates that the BLA cannot be approved in its present form, as the FDA determined that substantial evidence of effectiveness is not established in the absence of a statistically…2026-11-16SEC EDGAR 8-K 0001599298-26-000092 (text as filed, excerpt)2026-11-21 11:32 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-04)On November 4, 2026, Summit Therapeutics Inc. (the “Company”) issued a press release announcing its financial results and operational progress for the third quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02 as if fully set forth herein. In accordance with General Instruction B.2 of Form 8-K, the information set forth under Item 2.02 and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed…2026-11-04SEC EDGAR 8-K 0001599298-26-000088 (text as filed, excerpt)2026-11-21 11:32 UTCReport an error
8-K Item 5.03 (filed 2026-11-04)Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. As described in Item 5.07 below, on November 4, 2026, the Company held its Special Meeting of Stockholders (the “Special Meeting”), at which the Company’s stockholders approved an amendment (“Amendment No. 3”) to the Company’s Restated Certificate of Incorporation to increase the number of authorized shares of the Company’s common stock by 1,000,000,000 (from 1,000,000,000 to 2,000,000,000). On November 4, 2026, the Company filed Amendment No. 3 with the Secretary of State of the State of Delaware, which became effective upon filing. The foregoing description of Amendment No. 3 does not purport to be complete and is…2026-11-04SEC EDGAR 8-K 0001599298-26-000088 (text as filed, excerpt)2026-11-21 11:32 UTCReport an error
8-K Item 5.07 (filed 2026-11-04)Submission of Matters to a Vote of Security Holders. On November 4, 2026, the Company held the Special Meeting. The stockholders of the Company of record as of the close of business on October 1, 2026 were asked to vote on Amendment No. 3, which would increase the number of authorized shares of the Company’s common stock by 1,000,000,000 (from 1,000,000,000 to 2,000,000,000) (the “Proposal”). The Proposal was approved at the Special Meeting by the requisite vote of the Company’s stockholders in accordance with the recommendation of the Company’s Board of Directors. Set forth below is the number of votes cast for, against, as well as the number of abstentions and broker non-votes, as to the…2026-11-04SEC EDGAR 8-K 0001599298-26-000088 (text as filed, excerpt)2026-11-21 11:32 UTCReport an error
Employer name (as filed)Summit Therapeutics Inc.2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:32 UTCReport an error
Certified LCAs32026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:32 UTCReport an error
Certified LCAs later withdrawn02026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:32 UTCReport an error
Total worker positions on certified LCAs32026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:32 UTCReport an error
Top job titles (title, LCA count)Sr Clinical Data Manager (2); Senior Manager, Clinical Data Management (1)2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:32 UTCReport an error
Wage offered, annualized (n, min, median, max)median $140,000 (range $140,000-$170,000, 3 filings)2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:32 UTCReport an error
Worksite statesNC; NJ2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:32 UTCReport an error
Plan (pension, plan no. 001)SUMMIT THERAPEUTICS INC. 401(K) PLAN: 284 participants, assets $21,466,3602025-12-31DOL EBSA Form 5500 public datasets (dataset)2026-11-21 11:32 UTCReport an error
Plan (welfare, plan no. 501)SUMMIT THERAPEUTICS HEALTH AND WELFARE BENEFITS PLAN: 242 participants2025-12-31DOL EBSA Form 5500 public datasets (dataset)2026-11-21 11:32 UTCReport an error
Largest institutional holder #1 (13F as filed): BAKER BROS. ADVISORS LP$477,697,0902026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:32 UTCReport an error
Largest institutional holder #2 (13F as filed): FMR LLC$146,340,3082026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:32 UTCReport an error
Largest institutional holder #3 (13F as filed): STATE STREET CORP$138,951,1182026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:32 UTCReport an error
Largest institutional holder #4 (13F as filed): BlackRock, Inc.$138,838,1272026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:32 UTCReport an error
Largest institutional holder #5 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$83,551,4322026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:32 UTCReport an error
Largest institutional holder #6 (13F as filed): UBS Group AG$76,256,4372026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:32 UTCReport an error
Largest institutional holder #7 (13F as filed): VANGUARD PORTFOLIO MANAGEMENT LLC$73,464,7082026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:32 UTCReport an error
Largest institutional holder #8 (13F as filed): GOLDMAN SACHS GROUP INC$65,760,2282026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:32 UTCReport an error
Largest institutional holder #9 (13F as filed): Point72 Asset Management, L.P.$53,876,9902026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:32 UTCReport an error
Largest institutional holder #10 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$49,950,1152026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:32 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.